StockData
Davion Healthcare PLC logo

Davion Healthcare PLC (DAVI) company profile

DAVINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Last filing: 20-F on Apr 30, 2026
$1.07+0.04 (+3.88%)

Close on Nov 18, 2026Market cap –P/E –Yield –

About Davion Healthcare

Surgical & Medical Instruments & Apparatus, SIC 3841

Davion Healthcare Plc is a healthcare technology company focused on developing early-warning, non-invasive Class I medical screening devices. Its product offerings include BreastCheck, an early indicator screening test utilizing thermochromic films, and FootFlow. The company operates through a licensing and distribution commercial model, partnering with regional and global licensees such as NeuRX Health Inc. to manage manufacturing, product marketing, retail distribution, customer support, and warranty obligations. Its target end users comprise individual consumers seeking preventative wellness insights as well as healthcare providers who review test results processed via smartphone applications and proprietary artificial intelligence servers.

The company is incorporated under the laws of the Republic of Ireland, maintaining its principal executive offices in Cork, Ireland. Product manufacturing designated for the North American market is situated in the United States, utilizing components sourced through local suppliers. As an emerging business, the enterprise has attained regulatory registration for initial offerings but has not launched commercial sales.

Summary of the business section of Davion Healthcare's latest annual report, written by StockData.

Company profile

Company

Legal name
Davion Healthcare PLC
Headquarters
Clonakilty, Ireland
Address
Unit A, West Cork Business & Technology Park P85 FV48
Phone
357 25040052
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
G4
Fiscal year ends
December 31
Auditor
Withum, Smith + Brown, PC, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
DAVI
Exchange
Nasdaq
Shares outstanding
25M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
2039072
CUSIP
G27599102
FIGI
BBG01WN61JR7
Share class FIGI
BBG01WN61L47
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jack Harry KayeCHIEF EXECUTIVE OFFICER, Director10,268,948
Julian SluytersDirector30,000
Susan M. KingDirector15,000

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 28, 2025ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?